Allison Hanna, DO
Family Medicine · Bountiful, UTNPI 1003080409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 25.1% of the total. Reporting peaked in 2019 at $409 and has fallen 96.1% since, to $16 in 2025.
Across 81 payments — averaging $13.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$281
- Novo Nordisk$155
- Astellas Pharma US Inc$152
- Boehringer Ingelheim$118
- GSK$72
- Sanofi-aventis U.S. LLC$62
- plus $278 from 11 others
Across 306 payments — averaging $1238.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$220K
- Sanofi Pasteur Inc.$64K
- Romark Laboratories, LC$54K
- Novo Nordisk AS$22K
- Pfizer$19K
What the payments were for
- Food & beverage$1,118100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $281 |
| Novo Nordisk | 15 | $155 |
| Astellas Pharma US Inc | 10 | $152 |
| Boehringer Ingelheim | 7 | $118 |
| GSK | 5 | $72 |
| Sanofi-aventis U.S. LLC | 5 | $62 |
| Merck | 4 | $61 |
| Johnson & Johnson | 4 | $59 |
| Amarin Pharma, Inc. | 2 | $29 |
| AstraZeneca | 2 | $25 |
| Pfizer | 2 | $23 |
| Eisai Inc. | 1 | $17 |
| Amgen | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$1,118 in reported general payments places this provider in the 60th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PaxlovidNirmatrelvir/Ritonavir | 16 | $1,331 |
| Celecoxib | 42 | $725 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 73 | $700 |
| Doxycycline Monohydrate | 47 | $409 |
| Gabapentin | 12 | $395 |
| Mupirocin | 36 | $392 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $376 |
| Ofloxacin | 17 | $329 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $326 |
| Ipratropium Bromide | 13 | $321 |
| Fluticasone Propionate | 24 | $287 |
| Cephalexin | 35 | $246 |
| Azithromycin | 55 | $179 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $145 |
| Fluconazole | 23 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPaxlovid | $23 | $1,33116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 928 family medicine providers in Utah.
Other family medicine in Bountiful
- Scott EricksonBountiful$101K
- Allen FreestoneBountiful$9K
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.